Wednesday, June 7, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

DTRA Awards George Mason $7.6M for Peptide Research

by Stephanie Lizotte
March 6, 2012

George Mason University (GMU) has been awarded a $7.6M contract for translational peptide research and development by the Defense Threat Reduction Agency (DTRA). The program goal is for development of novel broad-spectrum antimicrobials for use against combat wound infections and exposure to biothreat agents utilizing cationic antimicrobial peptides (CAMPs).

According to researchers at GMU, CAMPs are a natural time-tested model for defending against bacterial infections since bacteria have failed to develop widespread resistance to such peptides.  CAMPs are essential components in the first line of defense against infection in higher organisms, and constitute a valuable resource in the development of advanced broad-spectrum antimicrobials.

The research program will identify and produce new CAMPs, which in turn will be rigorously evaluated to determine their effectiveness in protecting against combat wound infections and biothreat agents.

The project will utilize GMU’s new state of the art GMU Biomedical Research Laboratory (BRL), a biocontainment laboratory featuring over 20,000 square feet of lab space managed by Mason’s National Center for Biodefense and Infectious Diseases (NCBID); and will leverage GMU’s unique capability to team across multidisciplinary lines such as nanoscience, bioinformatics, and systems biology.

The contract was awarded under HDTRA1-12-C-0039 and is expected to be completed by February 2017.

Tags: AntimicrobialsAwardsBioinformaticsBioterrorismDefense Threat Reduction Agency

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC